Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Moodys
Daiichi Sankyo
Federal Trade Commission
Dow
Deloitte
Julphar
McKesson
Harvard Business School

Generated: December 14, 2018

DrugPatentWatch Database Preview

Osimertinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for osimertinib mesylate and what is the scope of osimertinib mesylate patent protection?

Osimertinib mesylate is the generic ingredient in one branded drug marketed by Astrazeneca Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Osimertinib mesylate has eighty-one patent family members in thirty-eight countries.

There is one drug master file entry for osimertinib mesylate. One supplier is listed for this compound.

Summary for osimertinib mesylate
International Patents:81
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Suppliers / Packagers: 1
Bulk Api Vendors: 39
Patent Applications: 3
DailyMed Link:osimertinib mesylate at DailyMed
Synonyms for osimertinib mesylate
1421373-66-1
2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, methanesulfonate (1:1)
AK198680
AKOS026673944
AZD 9291 mesylate
AZD-9291 (Mesylate)
AZD-9291 mesylate
AZD-9291 mesylate pound Osimertinib Mereletinib)
AZD9291 mesylate
AZD9291 Ms salt, Osimertinib Ms salt; Mereletinib Ms salt
BC600811
CHEBI:90948
CHEMBL3545063
D10766
EX-A1577
FT-0699962
HY-15772A
KS-00000SU8
Mereletinib mesylate
MFCD28137994
MolPort-044-560-736
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate
N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide methanesulfonate
Osimertinib mesilate (JAN)
Osimertinib mesylate (USAN)
Osimertinib mesylate [USAN]
osimertinib methanesulfonate
osimertinib monomesylate
RDL94R2A16
SCHEMBL14661152
Tagrisso (TN)
UNII-RDL94R2A16

US Patents and Regulatory Information for osimertinib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-001 Nov 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Citi
Express Scripts
Colorcon
Cipla
Dow
Julphar
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.